Association between serum adropin level and burden of coronary artery disease in patients with non-ST elevation myocardial infarction

Abstract

Objective:Previous studies revealed the relationship between stable coronary artery disease (CAD) and serum adropin level, but this relationship has not been investigated in patients with non-ST segment elevation myocardial infarction (NSTEMI). The present study is an analysis of the relationship between adropin and severity of CAD assessed based on SYNTAX score in patients with NSTEMI.Methods:A total of 109 participants, 80 patients with NSTEMI and 29 healthy individuals, were prospectively enrolled in the study. Patients with NSTEMI were divided to 2 groups: high SYNTAX score (≥32) (35 patients) and low SYNTAX score (<32) (45 patients). Adropin level was measured from blood serum samples using enzyme-linked immunosorbent assay test.Results:Patients with NSTEMI and high SYNTAX score had significantly lower serum adropin level (2357.30 pg/mL±821.58) compared to NSTEMI patients with low SYNTAX score (3077.00 pg/mL±912.86) and control group (3688.00±956.65). Adropin cut-off value for predicting high SYNTAX score on receiver-operating characteristic curve analysis was determined to be 2759 pg/mL, with a sensitivity of 63% and a specificity of 57%. Adropin was an independent predictor for high SYNTAX score (odds ratio=0.999; 95% confidence interval: 0.998–1.000; p=0.007).Conclusion:Adropin could be an alternative blood sample value for predicting severity of CAD.

Association between serum adropin level and coronary artery disease: a systematic review and meta-analysis

“…These studies were screened layer by layer. Finally, there were seven studies included (8)(9)(10)(11)(12)(13)(14). The literature screening process and results are shown in Figure 1.…”

“…We are the first meta-analysis of the relationship between adropin and CAD so far in the world. A total of 7 casecontrol studies were included in this meta-analysis (8)(9)(10)(11)(12)(13)(14), including 525 CAD patients and 420 healthy controls. The results of meta-analysis showed that the levels of serum adropin in patients with CAD, AMI, UAP and SAP were significantly lower than those in healthy controls.…”

“…A total of seven studies were included (8)(9)(10)(11)(12)(13)(14). Meta-analysis of random effects model showed that serum adropin level in CAD group was lower than that in control group (SMD =−2.44, 95% CI: −3.87 to −1.01), P=0.0008) ( Figure 2).…”

New Peptides as Potential Players in the Crosstalk Between the Brain and Obesity, Metabolic and Cardiovascular Diseases

“…Numerous studies indicate that adropin influences cardiovascular system function and participates in the pathogenesis of several cardiovascular diseases ( Lovren et al, 2010 ; Topuz et al, 2013 ; Wu et al, 2014 ; Gu et al, 2015 ; Zhao et al, 2015 , 2016 ; Gulen et al, 2016 ; Ertem et al, 2017 ; Oruc et al, 2017 ; Bolayır et al, 2018 ; Sato et al, 2018 ; Altamimi et al, 2019 ; Thapa et al, 2019b ). Firstly, adropin determines the condition of the endothelial cells (EC).…”

Association between adropin and intima-to-media thickness in hypertensive patients with type 2 diabetes

“…Ertem A. G. et al on a group of patients with NSTEMI carried out the investigation, showed adropin's link with atherosclerosis. It resulted in a state that adropin plays a role in development of atherosclerotic burden in NSTEMI patients (14). Therewith, Çelik et al (15) demonstrated that lower serum adropin levels are associated with cardiac syndrome X (CSX).…”